Results 11 to 20 of about 158,005 (297)
Drugs in Context, 2017 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is mainly expressed in the liver but can also be found in the intestine and kidneys.
Constantine E Kosmas +5 more
doaj +2 more sources
Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus
Drugs in Context, 2018 Lipid-lowering therapy is used very commonly nowadays not only for the optimization of the lipid profile but also to reduce cardiovascular risk. However, some studies have linked the use of certain lipid-lowering agents with an increased risk for ...
Constantine E Kosmas +5 more
doaj +2 more sources
Lipid-lowering therapy: who can benefit
Vascular Health and Risk Management, 2011 Sandra J LewisNorthwest Cardiovascular Institute, Portland, OR, USAAbstract: Cardiovascular disease (CVD) is the leading cause of death in the US. Despite the decline in CVD-associated mortality rates in recent years, coronary heart disease (CHD) still ...
Lewis S
doaj +2 more sources
Рациональная фармакотерапия в кардиологии, 2015 Aim. To assess of lipid-lowering therapy with statins in very high cardiovascular risk patients admitted to hospital for coronary angiography and analyze lipid profiles depending on the intensity of lipid-lowering therapy. Material and methods.
N. E. Gavrilova +4 more
doaj +5 more sources
Three-year dynamics and unsolved problems of lipid-lowering therapy
Рациональная фармакотерапия в кардиологии, 2015 Aim. To study the lipid-lowering therapy, the adequacy of its control, as well as the awareness of patients at a high cardiovascular risk of atherosclerosis problems and the dynamics of these parameters in 3 years. Material and methods.
V. A. Sergeeva
doaj +5 more sources
Lipid-lowering therapy in membranous nephropathy [PDF]
Kidney International, 1999 Membranous nephropathy (MN) is a very common cause of nephrotic syndrome in adults, and lipid abnormalities are, therefore, frequently found in these subjects. Although efficient lipid-lowering therapy is available, almost nothing is known about the contribution of hyperlipidemia in the pathogenesis of progressive renal failure in MN.
Haas, Martin +2 more
openaire +3 more sources
Combined lipid-lowering therapy: choosing strategy and tactics
Кардиоваскулярная терапия и профилактика, 2010 Achieving target levels of low-density lipoprotein cholesterol (LDL-CH) with lipid-lowering therapy is the main component of the complex cardiovascular risk reduction, according to the Russian and international clinical guidelines.
N. A. Koziolova
doaj +2 more sources
MODERN ASPECTS OF LIPID LOWERING THERAPY: FOCUS ON INFLAMMATION
Медицинский совет, 2016 Lipid lowering therapy with statin use is one of the most important components in therapy of patients with lipid exchange disturbances. Great meaning is attributed not only to lipid-modifying but to the anti-inflammatory effect at their application ...
I. A. LIBOV +2 more
doaj +3 more sources
Кардиоваскулярная терапия и профилактика, 2021 Aim. To study lipid-lowering therapy in patients with high and very high risk of cardiovascular events (CVEs) at the outpatient and inpatient care stages in Irkutsk.Material and methods.
O. A. Ivanova +4 more
doaj +1 more source
Lipid-lowering therapy and percutaneous coronary interventions.
, 2021 Although technological and procedural advances have resulted in substantial improvements in clinical outcomes following percutaneous coronary interventions (PCI), recurrent coronary events may occur despite achieving optimal procedural results.
Mach, François +2 more
core +1 more source